Research Study Summary
A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to 12 Years Old
This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to <12 years (Groups 1 and 3, respectively), and 2 to <6 years (Groups 2 and 4, respectively).
To Learn more
CW ID: 223059
Date Last Changed:
February 10, 2017
Clinical Trial Snapshot
- Both Male and Female
- Overall Status
- Merck Sharp & Dohme Corp
- Facility Type
- Receiving prophylaxis for or with a confirmed or suspected infection with Gram-positive bacteria and receiving concurrent antibiotic treatment with Gram-positive antibacterial activity;
- Weight >5th percentile and <95th percentile based on age;
- Stable condition as determined from medical history, physical examination, minimally 5-lead ECG, vital signs, and clinical laboratory evaluations;
- Females must be premenarchal, abstinent, or practicing an effective method of birth control.
- History of seizures, other than febrile seizures, clinical significant cardiac arrhythmia, cystic fibrosis, moderate or severe renal impairment, or any physical condition that could interfere with the study results;
- Recent (3 month) history or current infection with viral hepatitis or other significant hepatic disease;
- History of drug allergy or hypersensitivity to oxazolidinones;
- Pregnant or breast feeding;
- Significant blood loss within 60 days prior to study start;
- Any acute or chronic condition that would limit the participant's ability to complete and/or participate in this clinical study.
- Treatment with investigational medicinal product within 30 days before the infusion/dose of study drug.
- Oral administration of methotrexate, topotecan, irinotecan or rosuvastatin, during administration of oral study drug. Administration during the follow-up period is allowed, as is administration during treatment with IV study drug.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.